Okiyama M, Ueno K, Ohkawara S, Ohmori S, Igarashi T, Kitagawa H
J Pharm Sci. 1986 Nov;75(11):1071-5. doi: 10.1002/jps.2600751110.
The effects of daily oral administration of imipramine hydrochloride (5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz-[b,f]azepine monohydrochloride; 50 mg/kg) and/or diazepam (7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one ; 5 mg/kg) in a 1% aqueous solution of carboxymethylcellulose sodium salt (CMC) on the body weight, organ weights, and activities of various enzymes, including drug metabolizing enzyme systems were investigated in rats during a 15-day period. The plasma concentrations of imipramine and desipramine were also determined. In addition, the effect of a single intravenous administration of imipramine hydrochloride (5 mg/kg) on the plasma concentration-time profiles of imipramine and desipramine was investigated in rats given the same drug treatments. The plasma concentration-time profiles of imipramine and desipramine were analyzed pharmacokinetically. The rats treated with imipramine hydrochloride showed a greater inhibition of body weight gain than those treated with diazepam, and those treated with imipramine hydrochloride and diazepam simultaneously showed a body weight gain similar to those treated with imipramine hydrochloride alone. No significant differences in organ weight (per 100 g of body weight) were found. The imipramine hydrochloride plus diazepam treatment group showed a greater increase in drug-metabolizing enzyme activities than the imipramine hydrochloride treatment group, but the difference was not statistically significant. However, the plasma levels of imipramine and desipramine after oral administration for 15 d suggested that the imipramine hydrochloride plus diazepam treatment group did not show increased imipramine metabolism.(ABSTRACT TRUNCATED AT 250 WORDS)
在15天的时间里,研究了大鼠每日口服盐酸丙咪嗪(5-[3-(二甲氨基)丙基]-10,11-二氢-5H-二苯并[b,f]氮杂卓单盐酸盐;50毫克/千克)和/或地西泮(7-氯-1,3-二氢-1-甲基-5-苯基-2H-1,4-苯并二氮杂卓-2-酮;5毫克/千克)于1%羧甲基纤维素钠盐水溶液(CMC)中对体重、器官重量以及包括药物代谢酶系统在内的各种酶活性的影响。还测定了丙咪嗪和去甲丙咪嗪的血浆浓度。此外,在接受相同药物处理的大鼠中,研究了单次静脉注射盐酸丙咪嗪(5毫克/千克)对丙咪嗪和去甲丙咪嗪血浆浓度-时间曲线的影响。对丙咪嗪和去甲丙咪嗪的血浆浓度-时间曲线进行了药代动力学分析。接受盐酸丙咪嗪治疗的大鼠体重增加受到的抑制比接受地西泮治疗的大鼠更大,同时接受盐酸丙咪嗪和地西泮治疗的大鼠体重增加与仅接受盐酸丙咪嗪治疗的大鼠相似。未发现器官重量(每100克体重)有显著差异。盐酸丙咪嗪加地西泮治疗组的药物代谢酶活性增加幅度比盐酸丙咪嗪治疗组更大,但差异无统计学意义。然而,口服给药15天后丙咪嗪和去甲丙咪嗪的血浆水平表明,盐酸丙咪嗪加地西泮治疗组并未显示出丙咪嗪代谢增加。(摘要截断于250字)